Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a research note published on Friday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners started coverage on shares of Lipocine in a report on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price objective on the stock.

Lipocine Price Performance

Shares of LPCN stock opened at $5.01 on Friday. The business has a fifty day moving average of $5.10 and a 200 day moving average of $5.65. Lipocine has a 1 year low of $2.38 and a 1 year high of $11.79. The firm has a market capitalization of $26.80 million, a price-to-earnings ratio of -6.78 and a beta of 1.18.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter. As a group, equities research analysts expect that Lipocine will post -0.78 earnings per share for the current year.

Institutional Trading of Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP bought a new position in shares of Lipocine Inc. (NASDAQ:LPCN) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned approximately 0.22% of Lipocine as of its most recent SEC filing. 9.11% of the stock is owned by institutional investors and hedge funds.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.